Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59.
The Alzheimer’s drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis.
Drugs Performance
Biogen on Friday said fiscal 2025 revenue from growth products increased 19% year-over-year and offset the year-over-year revenue decline from multiple sclerosis products, excluding Vumerity.
Leqembi (Alzheimer’s drug) collaboration revenue was $47 million, with in-market sales of around $134 million, up 54%, booked by Eisai. U.S. in-market sales of approximately $78 million, representing continued growth.
Multiple sclerosis revenue of $917 million decreased by 14% (down 15% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $397.5 million from $415.4 million.
Rare disease revenue decreased 4% year over year (-4% on constant currency) to $514.6 million. Spinraza’s revenue decreased to $356.2 million from $421.4 million a year ago.
Spinraza’s …